Difficulty: Medium
Average Score: 92%
Practice
Which of the following chromosomal abnormalities of childhood ALL carries the highest risk of relapse despite intensive chemotherapy?
Correct answer
A
Rationale
In pediatric oncology, understanding the different chromosomal abnormalities associated with childhood acute lymphoblastic leukemia (ALL) is crucial for determining appropriate treatment strategies and predicting outcomes.
The correct answer is A) t(9;22), also known as the Philadelphia chromosome. This abnormality results in the BCR-ABL1 fusion gene, which is associated with a high risk of relapse in childhood ALL despite intensive chemotherapy. This is because the presence of the Philadelphia chromosome confers resistance to standard treatments, leading to poor outcomes.
Option B) t(4;11) is associated with the MLL gene rearrangement and is generally considered a high-risk feature in childhood ALL due to its association with a poor prognosis. However, it does not carry the highest risk of relapse compared to t(9;22).
Option C) hypodiploidy, which refers to having fewer than the normal number of chromosomes, is also a high-risk feature in childhood ALL. It is associated with a poorer response to treatment but does not carry as high a risk of relapse as t(9;22).
Option D) t(1;19) is associated with the E2A-PBX1 fusion gene and is considered an intermediate-risk feature in childhood ALL. While it may impact treatment response, it does not carry the same level of relapse risk as t(9;22).
Educationally, understanding the significance of different chromosomal abnormalities in childhood ALL is essential for healthcare providers involved in the care of pediatric oncology patients. Recognizing the implications of these genetic alterations helps guide treatment decisions and prognostication, ultimately improving patient outcomes.
The correct answer is A) t(9;22), also known as the Philadelphia chromosome. This abnormality results in the BCR-ABL1 fusion gene, which is associated with a high risk of relapse in childhood ALL despite intensive chemotherapy. This is because the presence of the Philadelphia chromosome confers resistance to standard treatments, leading to poor outcomes.
Option B) t(4;11) is associated with the MLL gene rearrangement and is generally considered a high-risk feature in childhood ALL due to its association with a poor prognosis. However, it does not carry the highest risk of relapse compared to t(9;22).
Option C) hypodiploidy, which refers to having fewer than the normal number of chromosomes, is also a high-risk feature in childhood ALL. It is associated with a poorer response to treatment but does not carry as high a risk of relapse as t(9;22).
Option D) t(1;19) is associated with the E2A-PBX1 fusion gene and is considered an intermediate-risk feature in childhood ALL. While it may impact treatment response, it does not carry the same level of relapse risk as t(9;22).
Educationally, understanding the significance of different chromosomal abnormalities in childhood ALL is essential for healthcare providers involved in the care of pediatric oncology patients. Recognizing the implications of these genetic alterations helps guide treatment decisions and prognostication, ultimately improving patient outcomes.